Routine compliance filing for Q2 FY27 share dematerialisation certificate

Compliance View source PDF Explain this filing

REMUS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.2%Reaction day

₹975.50

prior close

₹941.55

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.8%-6.0% vs market

On the reaction day the stock moved 6.0 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.0

10m

-0.0

15m

+0.8

30m

-1.2

Sessions after the filingfrom the prior close

StockMarketvs market

Reaction day

-5.2+0.8-6.0

Next day

-5.3+1.0-6.3

+4.8+1.7+3.0

+3.2+0.1+3.2

+4.2+0.8+3.4

+0.5-0.9+1.4

-7.8-4.5-3.4

15d

———

UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Remus Pharmaceuticals filed a routine compliance certificate with NSE for the quarter ended September 30, 2026. The certificate was issued by their Registrar MUFG Intime India (formerly Link Intime), confirming that securities received for dematerialisation were processed and the related physical certificates were mutilated and cancelled as per SEBI regulations. This is a standard quarterly submission under Regulation 74(5) with no business or price-sensitive information.

Likely market impact

Routine regulatory filing only. No impact on shareholders, operations, or stock price.